- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Anne Bass, MD: Thromboembolic Events in Patients With Rheumatic Disease
Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why patients with rheumatic diseases are at risk for thromboembolism.
Transcript:
Why are thromboembolic events a special concern for patients with rheumatic disease?
So, we’ve learned that there’s a strong connection between the immune system inflammation and the clotting system. When your immune system is active, it actually makes you more prone to clotting. When patients have rheumatic diseases—not so much when they’re quiet, but when they’re active—almost any rheumatic disease, they’re at higher risk for blood clotting. It’s particularly true of conditions like granulomatosis with polyangiitis, which we used to call Wegener’s, but it’s really been shown to be the case with any rheumatic disease, including rheumatoid arthritis, for example, where the risk is about 2 and a half times when your disease is active than it would be if you didn’t have rheumatoid arthritis.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
